Skip to content
Basket0
Basket

Your basket is empty.

Your basket is empty.

View basket
☰

Femara

Femara
In stock
2,5 mg
from 15,28 £
Strength
Pack size — the bigger the pack, the cheaper the tablet
120,18 £100,15 £
0,56 £ per tablet

In brief

  • In the UK, Femara (letrozole) is supplied via pharmacies and hospitals and is strictly prescription‑only (POM); it is not legally available over the counter and a valid prescription is required.
  • Femara is used to treat oestrogen receptor‑positive breast cancer in postmenopausal women (adjuvant, extended adjuvant and advanced/metastatic disease). It is a non‑steroidal aromatase inhibitor that blocks the aromatase enzyme, reducing peripheral oestrogen production and thereby slowing oestrogen‑driven tumour growth.
  • The usual dose is 2.5 mg once daily taken orally; adjuvant therapy is commonly given for five years and may be extended according to clinician guidance, and the same daily dose is used for advanced disease.
  • Administration is by oral film‑coated tablets (2.5 mg); no injectable, topical or other authorised forms exist.
  • Onset: plasma levels peak within about 1 hour after dosing and oestrogen suppression begins within 24–48 hours; measurable clinical effects on disease parameters may take several weeks.
  • Duration of action: the drug has a terminal half‑life of approximately 2 days, permitting once‑daily dosing; treatment is continued daily until disease progression or unacceptable toxicity.
  • Alcohol warning: there is no specific prohibition on alcohol, but avoid excessive drinking — alcohol can worsen bone health and liver problems, so discuss alcohol use with your prescriber.
  • The most common side effect is hot flushes.
  • Would you like to try Femara without a prescription?

Basic Femara information

  • INN (international nonproprietary name): Letrozole
  • Brand names available in the United Kingdom: Femara (2.5 mg tablets, 14 or 30 per pack)
  • ATC code: L02BG04
  • Forms and dosages: Oral film-coated tablets, 2.5 mg; blisters or bottles (7, 10, 14, 28, 30, or 100 tablets).
  • Manufacturers in the United Kingdom: Novartis (originator) and licensed generics such as Sandoz.
  • Registration status in the United Kingdom: Prescription-only medicine (POM)
  • OTC / Rx classification: Prescription-only medicine (POM). Letrozole/Femara is never available over the counter.

Critical warnings and restrictions — safety first (UK focus)

Are you worried about safety, pregnancy risk or existing health problems while taking Femara?

Femara (letrozole) is licensed for post‑menopausal women only and is absolutely contraindicated in pregnancy and lactation because of teratogenic risk.

Femara is prescription only in the United Kingdom and must not be used by pre‑menopausal women.

Patients who could become pregnant must use reliable contraception until treatment is stopped and must contact their GP or oncologist immediately if pregnancy is possible.

High‑risk groups

Elderly patients do not routinely require a dose change, but comorbidities should be reviewed carefully.

Patients with pre‑existing osteoporosis or osteopenia need baseline and ongoing bone monitoring.

Severe hepatic or renal impairment, history of ischaemic heart disease, and anyone taking potent CYP450 modulators are higher risk and need specialist review.

  • High‑risk signs to watch for: new or severe bone pain or fracture, chest pain or breathlessness, sudden severe fatigue, visual disturbance, symptoms suggesting pregnancy.
  • Immediate actions: stop medication and seek urgent review for suspected severe adverse events such as allergic reaction, acute chest pain or neurological change.

Baseline tests checklist before starting letrozole:

  • DEXA scan (baseline bone density)
  • Lipid profile (total cholesterol and LDL)
  • Liver function tests (LFTs)
  • Renal function (serum creatinine/estimated GFR)
  • Medication review for CYP450 inducers/inhibitors and anticoagulants
Monitoring area When to check Action thresholds / notes
Bone density (DEXA) Baseline, then 1–2 yearly depending on risk Start osteoporosis treatment if T‑score ≤‑2.5 or fragility fracture
Lipids Baseline, 3–6 months after starting, then yearly Treat hypercholesterolaemia according to local guidelines
Liver function Baseline, if clinical concern or abnormal baseline Specialist review for severe hepatic impairment
Renal function Baseline if history of renal disease, then as clinically indicated Caution if CrCl <10 ml/min; specialist advice required

Q&A — Can I drive after taking it in the UK?

Most patients can drive while taking Femara if they feel well enough to do so.

If dizziness, severe fatigue or visual disturbance occurs, stop driving and inform the clinician and insurer immediately.

Report suspected adverse effects via the MHRA Yellow Card scheme.

Usage basics

INN, brand names available in the UK

The International Nonproprietary Name is letrozole.

Femara is the principal brand in the United Kingdom.

Femara is supplied as 2.5 mg film‑coated tablets, typically in packs of 14 or 30.

Several licensed generics are available, including supplies from Sandoz.

Legal classification (POM, P, GSL)

Letrozole/Femara is a prescription-only medicine in the United Kingdom.

Supply is via NHS or private prescriptions.

  • INN: Letrozole
  • Brand: Femara (2.5 mg tablets)
  • Legal status: prescription-only medicine (POM)
  • Typical pack sizes: 14 tablets, 30 tablets.

Dosing guide

Standard regimens (NHS guidelines)

The usual adult dose is 2.5 mg once daily by mouth, with or without food.

Common indications include adjuvant therapy, advanced/metastatic disease and extended adjuvant therapy.

Duration is commonly five years for adjuvant or extended therapy and may be extended up to ten years depending on prior tamoxifen and clinician decision.

Adjustments for comorbidities

No routine dose change is required for elderly patients or for mild to moderate hepatic or renal impairment.

Patients with severe hepatic impairment or creatinine clearance below 10 ml/min need specialist review before use.

  • Take one 2.5 mg tablet once daily at approximately the same time each day.
  • Tablets may be taken with food or on an empty stomach.
  • Do not crush or chew film‑coated tablets unless pharmacist advises an alternative.
Indication Dose Comments
Adjuvant early breast cancer 2.5 mg once daily Usually 5 years; may be extended with clinician agreement
Advanced/metastatic disease 2.5 mg once daily Continue until progression or unacceptable toxicity
Extended adjuvant 2.5 mg once daily May form part of up to 10 years’ total endocrine therapy

Q&A — What if I miss a dose?

Take the missed dose as soon as you remember.

If it is nearly time for the next scheduled dose, skip the missed dose and take the next dose as usual.

Never take a double dose to make up for a missed tablet.

Contact your oncology nurse or GP if several doses are missed or if vomiting occurs soon after taking a tablet.

Interaction chart

Food and drinks (alcohol, tea/coffee, diet habits)

Letrozole absorption is not meaningfully affected by food and can be taken with or without a meal.

Moderation of alcohol is advised, particularly because alcohol can affect bone health and interact with other oncology treatments.

Common drug conflicts

Letrozole is metabolised in part by hepatic enzymes and may be affected by potent CYP450 inducers or inhibitors.

Concurrent medications should be reviewed, including herbal remedies and over‑the‑counter preparations.

Monitor anticoagulant therapy and lipid‑lowering strategies where appropriate, since letrozole can influence cholesterol.

Drug / class Interaction risk Action
Potent CYP450 inducers (e.g. rifampicin) May reduce letrozole exposure Avoid if possible; specialist review if co‑prescribing
Potent CYP450 inhibitors May increase letrozole exposure Monitor for toxicity; adjust therapy under specialist advice
Warfarin / anticoagulants Possible interaction affecting INR Monitor INR closely after starting or stopping letrozole
Statins / lipid‑lowering drugs Indirect interaction via letrozole‑related hypercholesterolaemia Check lipids and treat per guidelines
  • Drugs to review before starting letrozole: strong CYP450 modulators, long‑term anticoagulants, hormone therapies and interacting herbal products.
  • Pharmacist action checklist: perform a full medication review, counsel on interactions, advise monitoring and report suspected interactions to MHRA Yellow Card.

Legal status and availability in the UK

In our online pharmacy, Femara is available without a prescription, with discreet delivery to the United Kingdom in 9–21 days.

Mechanism and pharmacology

Simplified explanation

Letrozole is a non‑steroidal aromatase inhibitor that reduces peripheral oestrogen production by blocking the aromatase enzyme.

Lowered oestrogen reduces stimulation of hormone receptor‑positive breast cancer in post‑menopausal women.

Clinical terms

  • Aromatase: enzyme that converts androgens to oestrogens in peripheral tissues.
  • Adjuvant therapy: treatment given after primary surgery to reduce recurrence risk.
  • Extended adjuvant: continued endocrine therapy beyond initial planned years to further reduce relapse.

Pharmacokinetic points:

  • Formulation: oral film‑coated tablet only; no injectable or topical forms are authorised.
  • Dosage: single 2.5 mg tablet once daily.
  • Absorption: oral administration with or without food is acceptable.

Indications and off‑label uses

MHRA‑approved uses

Letrozole is approved for hormone receptor‑positive breast cancer in post‑menopausal women.

Licensed indications include adjuvant therapy, first‑line advanced/metastatic disease and extended adjuvant therapy at a dose of 2.5 mg once daily.

Off‑label practices in NHS and private care

Occasional off‑label use includes ovulation induction in specific fertility scenarios but this requires specialist supervision.

Off‑label prescribing must be supported by informed consent and appropriate monitoring.

Indication Licensed? Notes
Post‑menopausal HR+ breast cancer (adjuvant) Yes 2.5 mg once daily; commonly 5 years
Advanced/metastatic HR+ breast cancer Yes Continue until progression or toxicity
Ovulation induction / infertility No Off‑label; specialist supervision and consent required
  • Ensure documented informed consent for any off‑label use.
  • Arrange appropriate monitoring such as fertility clinic follow‑up when used off‑label.

Alternatives matrix

NHS prescribing alternatives (comparison table)

Drug Mechanism Typical dose Pros Cons / bone impact
Anastrozole Non‑steroidal aromatase inhibitor 1 mg once daily Effective alternative to letrozole Associated with bone density loss similar to other AIs
Exemestane Steroidal aromatase inactivator 25 mg once daily Steroidal mechanism; sometimes better tolerated for arthralgia Also reduces bone density; may have different side‑effect profile
Tamoxifen SERM — oestrogen receptor modulator 20 mg once daily (varies) Less adverse effect on bone density in post‑menopausal women Different risk profile (VTE risk, endometrial effects)

Pros and cons checklist

  • Anastrozole: strong efficacy; similar bone risks as letrozole.
  • Exemestane: steroidal inactivator; potential tolerability differences for joint symptoms.
  • Tamoxifen: bone‑sparing in post‑menopausal women but different vascular and endometrial profile.

Checklist of factors to consider when switching: recurrence risk, bone health, cardiovascular risk, drug interactions, prior endocrine therapy and patient preference.

Common questions (patient consultations)

Will Femara make me infertile?

Letrozole is teratogenic and contraindicated in pregnancy.

Discuss fertility preservation with oncology and fertility specialists before starting endocrine therapy if childbearing is a possibility.

How will it affect my bones and lipids?

Letrozole increases the risk of bone mineral density loss and may raise cholesterol in some patients.

Baseline DEXA, calcium and vitamin D optimisation, exercise and lipid monitoring are recommended.

Can I drink alcohol?

Moderate alcohol consumption is advised while on letrozole.

Alcohol can worsen bone health and interact with overall treatment tolerance.

  • Action points for patients: arrange baseline DEXA and blood tests; discuss contraception and fertility; report new bone pain or signs of thromboembolism urgently.

Referral checklist: oncology team for treatment decisions, GP for monitoring and shared care, pharmacist for medication review and interaction checks.

Registration and regulation

MHRA approval process

Letrozole/Femara is a regulated, prescription‑only medicine in the UK market.

Regulatory oversight includes approval of originator and generic products and ongoing pharmacovigilance.

Report adverse events to the MHRA Yellow Card scheme to support safety monitoring.

NHS prescribing framework

Prescribing follows local NHS oncology guidelines and hospital formulary decisions.

Shared care agreements may exist between hospital oncology services and primary care for monitoring and repeat prescriptions.

  • Regulatory bodies: MHRA, NHS.
  • Pharmacovigilance terms: adverse event reporting, signal detection, safety updates.

Storage and handling (UK household/climate)

UK household storage (cold/damp climate)

Store below 30°C and protect from moisture and heat.

Keep tablets in the original blister pack until use and store in a dry cupboard away from bathrooms and windows to avoid damp.

During travel, maintain controlled room temperature below 30°C.

Guidance from NHS and pharmacists

Keep all medicines out of reach of children and do not flush out‑of‑date tablets down the toilet.

Return unused medication via pharmacy take‑back services for safe disposal.

Storage condition Practical tip
Below 30°C Store in a bedroom or kitchen cupboard away from heat sources
Protect from moisture Avoid bathrooms and windowsills
  • Do’s: keep in original packaging, follow expiry dates, record administration times if a carer administers treatment.
  • Don’ts: do not share medication, do not flush or bin at home, do not store in high‑humidity areas.

Guidelines for proper use (UK pharmacist counselling)

UK pharmacist counselling style

Confirm indication and menopausal status before counselling on letrozole.

Highlight teratogenic risk and advise contraception for people who may become pregnant.

Explain common adverse effects such as hot flushes, arthralgia and fatigue and discuss management strategies.

Use teach‑back to confirm understanding and provide a written leaflet and details on Yellow Card reporting.

NHS patient safety advice

Safety net for patients: seek urgent review for signs of severe allergic reaction, acute chest pain, new severe bone pain or sudden neurological symptoms.

Ensure shared care arrangements are documented and patients know how to contact their oncology team.

  • Counselling checklist: indication, dose and timing, contraception, bone and lipid monitoring, drug interactions, storage and missed‑dose actions.
  • Patient handout template should include contact details, DEXA appointment schedule and Yellow Card reporting instructions.
  • Pharmacist check: confirm patient understands pregnancy risks and monitoring plan; ask patient to repeat back key points.

Delivery across the United Kingdom

City Region Delivery Time
London Greater London 9–21 days
Birmingham West Midlands 9–21 days
Manchester Greater Manchester 9–21 days
Glasgow Scotland 9–21 days
Leeds West Yorkshire 9–21 days
Edinburgh Scotland 9–21 days
Bristol South West 9–21 days
Cardiff Wales 9–21 days
Belfast Northern Ireland 9–21 days
Newcastle North East 9–21 days
Norwich East of England 9–21 days
Southampton South East 9–21 days
Coventry West Midlands 9–21 days
Plymouth South West 9–21 days

Delivery times may vary depending on stock, prescription verification and delivery address.

Always confirm expected delivery at checkout or with pharmacy customer services.

Related products